Troubled by deaths, FDA orders Merck to slam the brakes on three Keytruda studies
A month after Merck flagged a higher risk of death in two combo studies using its flagship drug Keytruda, the FDA has followed up with a clinical hold that will slam the brakes on further treatment in three multiple myeloma trials.
Merck said a few weeks ago that it planned to continue treatment in the two studies – KEYNOTE 183 and KEYNOTE 185 – while pausing enrollment of new patients. Those multiple myeloma trials matched Merck’s blockbuster therapy with two drugs from Celgene, Pomalyst and its big drug Revlimid.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.